Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?

To: AT7 who wrote (59)	11/9/1998 11:26:00 AM
From: W Shakespeare	Respond to of 101

More news to be happy about: Akorn in Marketing Alliances With Allergan & Allegiance for U.S. Launch of Biolon Product NEW ORLEANS--(BUSINESS WIRE)--Nov. 9, 1998-- Akorn's Ophthalmic Division Unveils Its New Identity "Delivering a Better Way" Akorn, Inc. (NASDAQ: AKRN)--At the annual meeting of the American Academy of Ophthalmology, Akorn, Inc.(NASDAQ: AKRN) today announced the launch of a proprietary ophthalmic product in the U.S., BioLon(TM) with two marketing partners, Allergan and Allegiance. This announcement was made in conjunction with the unveiling at the meeting of a new corporate identity for Akorn's ophthalmic division based on the theme, "Delivering a Better Way." BioLon(TM) is a medical device indicated as a surgical aid for cataract extraction, intraocular lens implantation and anterior segment surgery. Akorn, Inc. acquired the exclusive license to sell BioLon(TM) in the United States from Biotechnology General Corporation (NASDAQ: BTGC) in April of 1998. Since 1993, BioLon(TM) has been used in ocular surgery in 26 countries for over one million procedures. The U.S. market for viscoelastics is approximately $100 million annually. In order to penetrate this market, Akorn has formed marketing partnerships with two leading U.S. companies--Allergan, Inc. and the Custom Sterile Pack Division of Allegiance Healthcare. The combined sales forces of Akorn, Allergan and Allegiance, over 200 sales representatives, will be promoting BioLon(TM) to the ophthalmic market. R. Scott Zion, Senior VP and General Manager of Akorn Ophthalmics said, "We are extremely excited about our new identity as a company, "Delivering a Better Way." We are launching BioLon(TM), which has the potential to be the biggest selling product in our line. And, we have forged solid marketing alliances with Allergan and Allegiance to make BioLon(TM) a success in the U.S." Akorn, Inc. manufactures and markets sterile ophthalmic and injectable pharmaceuticals, and markets and distributes an extensive line of ophthalmic products. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from anticipated results as a result of certain risks and uncertainties, including but not limited to the effects of federal, state and other government regulation of the Company's business; the Company's success in acquiring, developing, manufacturing and marketing new products; the effects of competition from generic pharmaceuticals and other pharmaceutical companies; and other risks and uncertainties identified in the Company's Securities and Exchange Filings. This release is available on the KCSA Worldwide website at www.kcsa.com. CONTACT: Akorn, Inc., New Orleans Rita McConville, Chief Financial Officer 847/279-6151 or KCSA Worldwide, New York Paul Holm or Joseph A. Mansi 212/682-6300 KEYWORD: LOUISIANA BW1279 NOV 09,1998 7:29 PACIFIC 10:29 EASTERN